Roche, Rona Ink $1.06 Billion ALK7 RNAi Deal for Obesity

Rona Therapeutics (Rona) announced October 13, 2026, that it has granted Roche an exclusive worldwide license for Rona's investigational RNA interference (RNAi) candidate targeting activin receptor-like kinase 7 (ALK7) for treating obesity and metabolic diseases.¹ The candidate uses Rona's proprietary extrahepatic delivery platform.

Under the agreement, Rona will receive upfront and near-term milestone payments of up to $100 million. It is also eligible to receive up to $1.06 billion in additional development, regulatory, and commercial milestone payments, plus tiered royalties on global net sales.¹

"ALK7 is a compelling obesity and metabolic disease target with the potential to directly address adipose tissue biology," said Stella Shi, CEO and founder of Rona Therapeutics, in a company press release.¹ "This collaboration combines Rona's pioneering extrahepatic RNAi R&D platform with Roche's strong expertise and commitment in global development and commercialization of medicines for the treatment of obesity and metabolic diseases to bring this important therapeutic candidate to patients."

What is ALK7, and why is it a validated target for obesity?

ALK7, encoded by the ACVR1C gene, is a member of the transforming growth factor-beta receptor superfamily and is expressed predominantly in adipose tissue, where it regulates lipid storage, lipolysis, and energy homeostasis.¹ Human genetic evidence supports the target. For example, in an analysis of more than 300,000 UK Biobank participants, carriers of ACVR1C coding variants had a lower waist-to-hip ratio and up to 30% lower risk of type 2 diabetes, and carriers of predicted damaging variants in a separate exome-sequencing cohort had a 54% lower risk, consistent with reduced ALK7 activity protecting against adverse fat distribution and metabolic disease.²

How does this approach differ from existing obesity treatments?

Unlike incretin-based therapies, such as glucagon-like peptide-1 receptor agonists, which act primarily in the central nervous system to reduce appetite and energy intake,³ ALK7 inhibition is designed to act directly on adipocytes, with the potential to selectively reduce visceral and other ectopic fat depots while preserving lean mass.¹ Rona and Roche describe this mechanism as potentially complementary to, rather than purely competitive with, incretin drugs, raising the possibility of combination use.¹

What else is in Rona's pipeline?

Founded in 2021, Rona has raised roughly $200 million from healthcare investors and strategic partners and has advanced 4 programs into clinical development using its extrahepatic delivery, multi-valency, and oligo chemistry platforms.⁴ Its most advanced obesity program, RN3161, a short interfering RNA targeting INHBE, completed dosing of its first cohort in a phase 1, randomized, double-blind, placebo-controlled trial in December 2025, with Rona reporting a favorable initial safety and tolerability profile. Additional cohorts are expected in 2026.⁴

"We are excited to partner with Rona Therapeutics, complementing our robust CVRM [cardiovascular, renal, and metabolic] pipeline and reinforcing our commitment to delivering next-generation metabolic therapies," said Boris L. Zaïtra, head of corporate business development at Roche, in the release.¹

What are the limitations?

The licensed ALK7 candidate has not been named or disclosed to be in clinical testing, unlike Rona's INHBE program, so no human safety or efficacy data exist for it yet.¹ The human genetic associations between ACVR1C variants and metabolic outcomes do not necessarily guarantee that RNAi-mediated silencing of ALK7 will replicate those effects therapeutically or prove safe in patients.² The $1.06 billion milestone figure represents the maximum potential payment contingent on development, regulatory, and commercial success, not a guaranteed sum.¹ Roche, as exclusive worldwide licensee, now controls the candidate's further development and commercialization timeline.¹

References

1. Rona Therapeutics. Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases. Press release. Published October 13, 2026. Accessed October 13, 2026. https://www.prnewswire.com/news-releases/rona-therapeutics-enters-into-global-license-agreement-with-roche-for-alk7-targeting-rnai-therapy-for-obesity-and-metabolic-diseases-302905730.html
2. Emdin CA, Khera AV, Aragam K, et al. DNA sequence variation in ACVR1C encoding the activin receptor-like kinase 7 influences body fat distribution and protects against type 2 diabetes. Diabetes. 2019;68(1):226-234. doi:10.2337/db18-0857
3. Bailey T. Incretin-based therapies for type 2 diabetes: comparisons between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. US Endocrinology. 2011;7(2):82-94. doi:10.17925/USE.2011.07.02.82
4. Rona Therapeutics. Rona Therapeutics advances INHBE siRNA into phase 1 clinical development. Press release. Published December 15, 2025. Accessed October 13, 2026. https://www.ronatherapeutics.com/news/41